| Product Code: ETC13199594 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Visceral Leishmaniasis Market was valued at USD 1.2 Billion in 2024 and is expected to reach USD 1.7 Billion by 2031, growing at a compound annual growth rate of 14.90% during the forecast period (2025-2031).
The global visceral leishmaniasis market is driven by the increasing prevalence of the disease in regions such as Africa, Asia, and Latin America. The market is characterized by the presence of key players developing and commercializing treatments, including drugs such as miltefosine, amphotericin B, and liposomal amphotericin B. Diagnostic tests such as polymerase chain reaction (PCR) and serological tests also contribute to market growth. Government initiatives and collaborations with non-profit organizations further support market expansion by raising awareness, improving diagnosis rates, and ensuring access to treatment in endemic regions. However, challenges such as limited treatment options, drug resistance, and lack of healthcare infrastructure in some areas hinder market growth. Overall, the global visceral leishmaniasis market is expected to witness steady growth due to ongoing research efforts and increasing focus on disease control programs.
The Global Visceral Leishmaniasis Market is seeing a growing focus on research and development for innovative treatment options, including new drug formulations and vaccines. With increasing awareness about the disease and improved diagnostic methods, there is a rising demand for effective and affordable treatments. The market is also witnessing collaborations between pharmaceutical companies, research institutions, and government organizations to accelerate drug development and improve patient outcomes. Additionally, the emergence of public-private partnerships and initiatives to address neglected tropical diseases presents opportunities for market growth. As governments and healthcare organizations strive to control and eliminate visceral leishmaniasis, there is a growing emphasis on improving access to healthcare services in endemic regions, which could further drive market expansion.
The Global Visceral Leishmaniasis Market faces several challenges, including limited awareness about the disease in some regions, leading to delayed diagnosis and treatment. Access to proper healthcare facilities and diagnostic tools is also a major challenge, particularly in resource-constrained areas where the disease is endemic. Additionally, the lack of effective vaccines and limited treatment options, coupled with the emergence of drug-resistant strains of the Leishmania parasite, pose significant obstacles in managing and controlling the disease. Furthermore, the high cost of existing treatments and the relatively low investment in research and development for new therapies hinder progress in addressing visceral leishmaniasis. Overcoming these challenges will require concerted efforts from healthcare providers, governments, research institutions, and pharmaceutical companies to improve diagnosis, treatment accessibility, and research initiatives.
The global visceral leishmaniasis market is primarily driven by factors such as increasing prevalence of the disease in endemic regions, growing awareness initiatives by government and non-government organizations, and rising research and development activities for the development of novel treatments. Additionally, advancements in diagnostic technologies, improved healthcare infrastructure in developing countries, and collaborations between pharmaceutical companies and research institutions are also contributing to the market growth. Furthermore, the high demand for effective and safe treatment options, along with the availability of supportive reimbursement policies in some regions, are expected to fuel the market expansion for visceral leishmaniasis therapeutics in the coming years.
Government policies related to the Global Visceral Leishmaniasis Market typically focus on prevention, control, and treatment strategies to combat the spread of the disease. These policies may include initiatives for surveillance, diagnosis, and management of visceral leishmaniasis, as well as efforts to improve access to healthcare services and essential medications. Governments often collaborate with international organizations and non-governmental agencies to implement integrated control programs, raise public awareness, and strengthen healthcare systems in endemic regions. Additionally, regulatory measures may be in place to ensure the quality and safety of drugs and vaccines used in the treatment of visceral leishmaniasis. Overall, government policies play a crucial role in addressing the challenges posed by this neglected tropical disease and in promoting research and innovation for more effective control and elimination strategies.
The Global Visceral Leishmaniasis Market is expected to see steady growth in the coming years due to factors such as increasing awareness about the disease, rising research and development activities for treatment options, and expanding healthcare infrastructure in developing regions. The market is likely to witness advancements in diagnostic tools, treatment options, and preventive measures, leading to improved patient outcomes and reduced disease burden. Additionally, collaborations between pharmaceutical companies, research institutions, and government organizations are anticipated to drive innovation and accelerate the development of novel therapies. However, challenges such as limited access to healthcare services in remote areas and high treatment costs may hinder market growth to some extent. Overall, the Global Visceral Leishmaniasis Market is poised for expansion with a focus on improving disease management and reducing transmission rates.
In the global visceral leishmaniasis market, different regions exhibit varying trends. In Asia, particularly in countries like India, Bangladesh, and Nepal, the disease burden is high, driving market growth for diagnostics, treatment, and prevention measures. North America and Europe have a lower prevalence of visceral leishmaniasis, but the market is driven by research and development efforts for new therapies and vaccines. In the Middle East and Africa, the disease is endemic in certain areas, leading to a focus on improving access to healthcare services and raising awareness. Latin America also faces challenges with visceral leishmaniasis, with countries like Brazil and Colombia investing in control programs and research initiatives to combat the disease. Overall, the global visceral leishmaniasis market is characterized by region-specific approaches to address the disease burden and improve patient outcomes.
Global Visceral Leishmaniasis Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Visceral Leishmaniasis Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Visceral Leishmaniasis Market Revenues & Volume, 2021 & 2031F |
3.3 Global Visceral Leishmaniasis Market - Industry Life Cycle |
3.4 Global Visceral Leishmaniasis Market - Porter's Five Forces |
3.5 Global Visceral Leishmaniasis Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Visceral Leishmaniasis Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.7 Global Visceral Leishmaniasis Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.8 Global Visceral Leishmaniasis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Global Visceral Leishmaniasis Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.10 Global Visceral Leishmaniasis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Global Visceral Leishmaniasis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Visceral Leishmaniasis Market Trends |
6 Global Visceral Leishmaniasis Market, 2021 - 2031 |
6.1 Global Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Cutaneous Leishmaniasis, 2021 - 2031 |
6.1.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Mucosal Leishmaniasis, 2021 - 2031 |
6.1.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By Visceral Leishmaniasis, 2021 - 2031 |
6.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Antiparasitic, 2021 - 2031 |
6.2.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Antifungal, 2021 - 2031 |
6.2.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Oral, 2021 - 2031 |
6.3.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Injectable, 2021 - 2031 |
6.3.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.4.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Homecare, 2021 - 2031 |
6.4.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By Specialty Clinics, 2021 - 2031 |
6.4.5 Global Visceral Leishmaniasis Market, Revenues & Volume, By Others, 2021 - 2031 |
6.5 Global Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 Global Visceral Leishmaniasis Market, Revenues & Volume, By Hospital Pharmacy, 2021 - 2031 |
6.5.3 Global Visceral Leishmaniasis Market, Revenues & Volume, By Online Pharmacy, 2021 - 2031 |
6.5.4 Global Visceral Leishmaniasis Market, Revenues & Volume, By Retail Pharmacy, 2021 - 2031 |
7 North America Visceral Leishmaniasis Market, Overview & Analysis |
7.1 North America Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
7.2 North America Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.4 North America Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
7.5 North America Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.6 North America Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
7.7 North America Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 Latin America (LATAM) Visceral Leishmaniasis Market, Overview & Analysis |
8.1 Latin America (LATAM) Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
8.4 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
8.5 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
8.6 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
8.7 Latin America (LATAM) Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
9 Asia Visceral Leishmaniasis Market, Overview & Analysis |
9.1 Asia Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
9.4 Asia Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
9.5 Asia Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
9.6 Asia Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
9.7 Asia Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
10 Africa Visceral Leishmaniasis Market, Overview & Analysis |
10.1 Africa Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
10.4 Africa Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
10.5 Africa Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
10.6 Africa Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
10.7 Africa Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
11 Europe Visceral Leishmaniasis Market, Overview & Analysis |
11.1 Europe Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
11.4 Europe Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
11.5 Europe Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
11.6 Europe Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
11.7 Europe Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
12 Middle East Visceral Leishmaniasis Market, Overview & Analysis |
12.1 Middle East Visceral Leishmaniasis Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Visceral Leishmaniasis Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
12.4 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By Treatment, 2021 - 2031 |
12.5 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
12.6 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By End User, 2021 - 2031 |
12.7 Middle East Visceral Leishmaniasis Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
13 Global Visceral Leishmaniasis Market Key Performance Indicators |
14 Global Visceral Leishmaniasis Market - Export/Import By Countries Assessment |
15 Global Visceral Leishmaniasis Market - Opportunity Assessment |
15.1 Global Visceral Leishmaniasis Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Visceral Leishmaniasis Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
15.3 Global Visceral Leishmaniasis Market Opportunity Assessment, By Treatment, 2021 & 2031F |
15.4 Global Visceral Leishmaniasis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
15.5 Global Visceral Leishmaniasis Market Opportunity Assessment, By End User, 2021 & 2031F |
15.6 Global Visceral Leishmaniasis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
16 Global Visceral Leishmaniasis Market - Competitive Landscape |
16.1 Global Visceral Leishmaniasis Market Revenue Share, By Companies, 2024 |
16.2 Global Visceral Leishmaniasis Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here